Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
stocks
Does this bank have what it takes to compete with the big 4?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,891.10 | 5.00 | -0.06% |
| CAC 40 | 8,108.43 | 6.31 | -0.08% |
| DAX 40 | 24,046.01 | 17.87 | 0.07% |
| Dow JONES (US) | 47,739.32 | 215.67 | -0.45% |
| FTSE 100 | 9,645.09 | 21.92 | -0.23% |
| HKSE | 25,542.34 | 223.02 | -0.87% |
| NASDAQ | 23,545.90 | 32.22 | -0.14% |
| Nikkei 225 | 50,737.98 | 156.04 | 0.31% |
| NZX 50 Index | 13,429.98 | 56.34 | -0.42% |
| S&P 500 | 6,846.51 | 23.89 | -0.35% |
| S&P/ASX 200 | 8,601.50 | 4.90 | -0.06% |
| SSE Composite Index | 3,918.83 | 5.25 | -0.13% |